

DATINVEST INTERNATIONAL LTD.
Suite 918, 1030 West Georgia Street
Vancouver, British Columbia
V6E 2Y3

NEWS RELEASE

DATINVEST ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE EXXEL PHARMA

June 11, 2018 – Vancouver, British Columbia – Datinvest International Ltd. (TSXV: DAI.H) (the “**Company**”) is pleased to announce that it has entered into a definitive amalgamation agreement, effective June 6, 2018 (the “**Definitive Agreement**”), with Exxel Pharma Inc. (“**Exxel Pharma**”). Exxel Pharma is a privately held biopharmaceutical company, incorporated under the laws of the Province of British Columbia, focused on the development of therapeutics for the non-addictive treatment of pain, PTSD and substance addiction.

In accordance with the terms of the Definitive Agreement, Exxel Pharma will amalgamate with a wholly-owned subsidiary of the Company (the “**Business Combination**”), following which the resulting amalgamated entity will continue as a wholly-owned subsidiary of the Company. In consideration for completion of the Business Combination, all common shareholders of Exxel Pharma will be entitled to receive one (1) common share of the Company in exchange for every one (1) common share of Exxel Pharma that they hold. All outstanding share purchase warrants of Exxel Pharma will also be exchanged for share purchase warrants of the Company, and will be exercisable on substantially the same terms. In connection with completion of the Business Combination, it is anticipated that the Company will change its name to “Exxel Pharma Inc.”

For further information on Exxel Pharma, readers are encouraged to review the Company’s news release of May 22nd, and to visit: www.exxelpharma.com. Additional information on Exxel Pharma, including current financial statements, will be filed and posted on SEDAR upon the completion of a filing statement that will be prepared in connection with the Business Combination.

The Business Combination will constitute a reverse-takeover for the Company under the policies of the TSX Venture Exchange (the “**Exchange**”). Following completion of the Business Combination, it is anticipated that the Company would be listed on the Exchange as a Tier 2 Technology issuer. Closing of the Business Combination is subject to a number of conditions including completion of financing, receipt of all required regulatory and third party consents, including Exchange approval, and the satisfaction of other customary closing conditions. The Business Combination cannot close until the required approvals are obtained. There can be no assurance that the Business Combination will be completed as proposed or at all. Trading in the common shares of the Company will remain halted pending further filings with the Exchange.

Approval of the shareholders of the Company will not be required in connection with the Business Combination, in accordance with Exchange Policy 5.2, as the Business Combination is not a related party transaction and no other circumstances exist which may compromise the independence of the Company or other interested parties. The Company is listed on the NEX board of the Exchange, and shareholder approval is not required for any aspect of the Business Combination under applicable corporate or securities laws.

For further information, contact Emily Davis, Corporate Secretary of the Company, at 604.628.5616 or edavis@v1.ca, or Soren Mogelsvang, Chief Executive Officer of Exxel Pharma, at 720.261.1109 or soren.mogelsvang@exxelpharma.com.

On behalf of the Board,

Datinvest International Ltd.

Sean Davis, Chief Executive Officer

Completion of the Business Combination is subject to a number of conditions, including Exchange acceptance. There can be no assurance that the Business Combination will be completed as proposed or at all.

Investors are cautioned that, except as disclosed in the Filing Statement to be prepared in connection with the Business Combination, any information released or received with respect to the Business Combination may not be accurate or complete and should not be relied upon. Trading in the securities of the Company should be considered highly speculative.

The TSX Venture Exchange has in no way passed upon the merits of the Business Combination and has neither approved nor disapproved the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.